Skip to main content
newcleo revenue skyrockets 26% to €10 million in Q3
Image for illustrative purposes only. Not a real photo.

newcleo revenue skyrockets 26% to €10 million in Q3

By

Key points

  • newcleo reported preliminary third-quarter 2026 product and service revenue of €10.0 million, up approximately 26% year over year, while completing installation of its core simulator in Italy.
  • Cash and cash equivalents increased to €233.4 million from €90.4 million a year earlier, while capital spending declined to approximately €11.3 million.
  • The commercial pipeline expanded to 10 GW, as newcleo advanced its nuclear fuel development activities, opened its FASTER development centre and established a fuel supply collaboration with Curio.

newcleo (NASDAQ:NWCL) reported preliminary third-quarter 2026 product and service revenue of €10 million, up approximately 26% year over year, as it completed installation of its core simulator in Italy.

Other income fell 75% to €2.9 million from €11.4 million, mainly because a previous grant ended, while capital expenditure declined to €11.3 million from €12.9 million and cash reached €233.4 million, compared with €90.4 million a year earlier.

The French Nuclear Safety and Radiation Protection Authority found the proposed safety measures for newcleo's planned mixed-oxide fuel manufacturing facility satisfactory at this stage, while the company completed installation of its electrically heated core simulator at its 10 MWth PRECURSOR prototype in Brasimone, Italy.

The later-stage commercial pipeline expanded to 10 gigawatts from approximately 9 gigawatts in mid-September, within total pipeline visibility of approximately 27 gigawatts across six countries, following an agreement with an Italian site developer.

After quarter-end, newcleo opened its €10 million FASTER fuel development centre in France, completed its acquisition of Bonifait Pesage and announced a collaboration with Curio to explore recycled nuclear material supplies for its planned US fuel manufacturing facility.


Frequently asked questions